Rociletinib
Rociletinib (pronounced roh-si-let-in-ib) is a pharmaceutical drug used in the treatment of non-small cell lung cancer (NSCLC). It is a third-generation epidermal growth factor receptor (EGFR) inhibitor, specifically designed to target mutant forms of the EGFR gene that have become resistant to first and second-generation EGFR inhibitors.
Etymology
The name "Rociletinib" is derived from the pharmaceutical company Clovis Oncology that developed the drug. The "rocil" part of the name is a tribute to the company, while "tinib" is a common suffix for tyrosine kinase inhibitors, which is the class of drugs to which Rociletinib belongs.
Usage
Rociletinib is used for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), who have progressed on or after EGFR TKI therapy. It is administered orally.
Mechanism of Action
Rociletinib inhibits the activity of the EGFR tyrosine kinase, which is a protein involved in the growth and spread of cancer cells. By inhibiting this protein, Rociletinib can slow down or stop the growth of NSCLC cells.
Side Effects
Common side effects of Rociletinib include diarrhea, nausea, vomiting, and fatigue. More serious side effects can include liver problems, heart problems, and eye problems.
Related Terms
- Non-small cell lung cancer (NSCLC)
- Epidermal growth factor receptor (EGFR)
- Tyrosine kinase inhibitors (TKIs)
- Clovis Oncology
External links
- Medical encyclopedia article on Rociletinib
- Wikipedia's article - Rociletinib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski